Atlas Trials

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Clinical trial NCT04632108 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04632108
Sponsor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Malignant Solid Tumor
Start date
2021-01-28
Primary completion
2025-10-31
Enrollment
199

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.